Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082868 · ClinicalTrials.gov registry record · Phase 1
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
A Phase 1 study of Central Nervous System Lymphoma and Primary Central Nervous System Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 8
- Study locations
NCT07082868 is a Phase 1 study of Central Nervous System Lymphoma and Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 26 participants, below the 104-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT07082868, a Phase 1 study of Central Nervous System Lymphoma and Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).
Conditions Studied
Interventions
- DRUG Epcoritamab
- DRUG ibrutinib
Study Locations (8)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07082868
The ClinicalTrials.gov registry entry for NCT07082868 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 14 other Central Nervous System Lymphoma trials with a reported enrollment target (75% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Central Nervous System Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Epcoritamab is the first listed.
NCT07082868 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Utah.
Frequently Asked Questions
What is clinical trial NCT07082868 about?
NCT07082868 is a clinical study titled "A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)". The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).
What is the current status of trial NCT07082868?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-08-13. Estimated completion is 2028-08.
What conditions does trial NCT07082868 study?
This clinical trial studies the following conditions: Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL).
What interventions are being tested in trial NCT07082868?
The interventions under investigation include: Epcoritamab (DRUG), ibrutinib (DRUG).
Who is sponsoring clinical trial NCT07082868?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082868 being conducted?
This trial has 8 study locations across New Jersey, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
-
Acalabrutinib in CNSL
ACTIVE NOT RECRUITING · Phase 1
-
Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)
COMPLETED · Phase 1
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
Explore more on PlainTrial
Central Nervous System Lymphoma
All registered trials for this condition
Primary Central Nervous System Lymphoma
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.